Paul Zachary Lamberty: Final Debarment Order
Published Date: 2/6/2026
Notice
Summary
Paul Zachary Lamberty is officially banned for 10 years from importing any drugs into the U.S. because he was convicted of serious crimes involving fake and misleading drugs. He didn’t respond to the FDA’s chance to defend himself, so the ban starts on February 6, 2026. If he wants to end the ban early, he can apply anytime but must be careful about sharing private info.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 2 costs, 1 mixed.
10-Year Import Ban for Lamberty
Paul Zachary Lamberty is banned for 10 years from importing or offering for import any drug into the United States. The debarment is effective February 6, 2026 and is based on his May 30, 2025 federal felony convictions for conspiracy and introduction of misbranded drugs with intent to defraud and mislead.
Importing With Lamberty Is Prohibited
Importing or offering for import any drug into the United States by, with the assistance of, or at the direction of Paul Zachary Lamberty is a prohibited act under section 301(cc) of the FD&C Act. This prohibition is effective February 6, 2026.
Termination Application & Confidentiality Rules
Mr. Lamberty may apply at any time to ask for early termination of the debarment under section 306(d)(1) of the FD&C Act. Applications submitted electronically will be posted publicly, so confidential information must be submitted as a written/paper submission following the FDA instructions to protect confidential material.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-02336, Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of Currently Approved Collection: Title-Campus Program Grantee Needs and Progress Assessment Tool
The Department of Justice’s Office on Violence Against Women is asking for more time to keep using a survey tool that helps campus program grantees track their needs and progress. They want your feedback on how this tool works and how to make it easier to use. If you’re involved in these programs, you can share your thoughts by April 7, 2026—no extra costs, just a chance to improve the process!
Next: 2026-02339, Codex Alimentarius Commission: Meeting of the Codex Committee on Methods of Analysis and Sampling
The U.S. Codex Office is hosting a public video meeting on February 19, 2026, to share info and gather feedback on food testing and sampling rules before the big Codex meeting in Hungary in March. This affects food producers, labs, and anyone interested in food safety standards. Joining the meeting and submitting comments helps shape U.S. positions, with no costs but important deadlines to keep in mind.